Company Description
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally.
The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables.
The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications.
In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software.
Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007.
The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 193 |
| CEO | Robert Spignesi |
Contact Details
Address: 1001 Pawtucket Boulevard West, Suite 280 Lowell, Massachusetts 01854 United States | |
| Phone | 978 349 3200 |
| Website | rapidmicrobio.com |
Stock Details
| Ticker Symbol | RPID |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001380106 |
| CUSIP Number | 75340L104 |
| ISIN Number | US75340L1044 |
| Employer ID | 20-8121647 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Robert G. Spignesi Jr. | Chief Executive Officer, President and Director |
| Sean M. Wirtjes | Chief Financial Officer |
| John J. Addington Wilson | Chief Operating Officer |
| Michael Beaulieu C.F.A. | Vice President of Investor Relations and Corporate Communications |
| James Xu | Vice President of Legal and Secretary |
| Michael Wysocki | Senior Vice President of Sales and Marketing |
| Kristine Williams | Senior Vice President of Product |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 1, 2024 | 8-K | Current Report |
| Aug 2, 2024 | 10-Q | Quarterly Report |
| Aug 2, 2024 | 8-K | Current Report |
| May 30, 2024 | SD | Form - SD |
| May 24, 2024 | 8-K | Current Report |
| May 3, 2024 | 10-Q | Quarterly Report |
| May 3, 2024 | 8-K | Current Report |
| Apr 9, 2024 | ARS | Filing |
| Apr 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |